Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 51Fallopian Tube Neoplasms 28Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 15Pancreatic Neoplasms 13Breast Neoplasms, Male 11Lung Neoplasms 10Brenner Tumor 10Inflammatory Breast Neoplasms 7Uterine Cervical Neoplasms 5Endometrial Adenocarcinoma 5Adenocarcinoma of Lung 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Cholangiocarcinoma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Pleural Effusion, Malignant 3Pancreatic Adenocarcinoma 3Neoplasms 3Thymoma 2Neurotoxicity Syndromes 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinosarcoma 2Breast Carcinoma In Situ 2

Interventions

Taxes 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreas Adenocarcinoma × Taxes × Clear all
NCT03377491 2026-01-21

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

NovoCure Ltd.

Phase 3 Completed
571 enrolled 22 charts
Gastrointestinal

Pancreas Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡